KPC1-p50 NF-κB Modulation for Controlled p105 Processing in Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing technologies have not adequately addressed the role of ubiquitin-mediated processing of NF-κB family of transcription factors in regulating cancer, particularly in the context of ubiquitination and proteasomal processing of p105 and its subunits p50 and p52, which are crucial for tumor suppression and regulation of immune and inflammatory responses.
Innovation Solution
The use of KPC1, a ubiquitin ligase with a specific sequence, and its related proteins or complexes, including p50, to regulate the ubiquitination and processing of p105, thereby modulating NF-κB activity for cancer treatment, potentially through fusion proteins, nucleic acids, or non-proteinaceous moieties, and administered in compositions with pharmaceutically acceptable carriers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If NF-κB is overexpressed to promote cell survival and proliferation, then tumor growth is enhanced, but tumor suppressive functions are lost
Solution Approach 1:
The patent extracts and utilizes the tumor suppressive function of NF-κB by selectively depleting the p65 subunit through targeted protein degradation. This allows retention of the p50 subunit which maintains tumor suppressive activities while eliminating the pro-survival functions, thus resolving the contradiction between proliferation promotion and tumor suppression.
Solution Approach 2:
The patent changes the functional parameters of NF-κB by altering the subunit composition through selective degradation of p65. This parameter change transforms NF-κB from a pro-tumorigenic state to a tumor suppressive state, enabling simultaneous control of proliferation and maintenance of suppressive functions.
2Productivity
If p105 is completely degraded to release NF-κB dimers, then transcriptional activation is enhanced, but processing control is lost
Solution Approach 1:
The patent extracts the controlled processing function by introducing a selective degradation mechanism that targets only the p65 subunit while preserving p50. This maintains precise control over NF-κB processing and dimer formation, preventing complete degradation of p105 while still enabling regulated release of functional dimers.
Solution Approach 2:
The patent employs an intermediary mechanism (targeted protein degradation system) that mediates between p105 processing and NF-κB dimer release. This intermediary allows controlled degradation of p65 to regulate dimer formation without complete degradation of p105, maintaining processing precision.
3Reliability
If ubiquitination and proteasomal processing are enhanced to generate p50, then tumor suppression is improved, but protein degradation burden increases
Solution Approach 1:
The patent extracts the tumor suppressive function from the general proteasomal degradation pathway by targeting specifically the p65 subunit for degradation. This selective approach maintains tumor suppression through enhanced p50 availability while minimizing the overall protein degradation burden on the proteasome system.
Solution Approach 2:
The patent applies local quality by directing protein degradation specifically at the p65 subunit rather than uniform degradation of all NF-κB components. This localized degradation strategy enhances tumor suppression through p50 while conserving proteasome capacity for other essential functions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The described approach effectively modulates NF-κB activity, leading to potential tumor suppression and cancer treatment by enhancing the processing of p105 into p50, thereby inhibiting cancer growth and proliferation.
Implementation Method 1
The family members are mostly heterodimers where one of the subunits - p52 or p50, is the product of limited, ubiquitin- and proteasome-mediated processing of a longer (and inactive) precursor, p100 or p105, respectively
Implementation Method 2
p105 is phosphorylated on serine residues 927 and 932 by IκB kinase (IKKβ). This modification recruits the beta-Transducin Repeat Containing Protein βTrCP E3, resulting in complete degradation of the molecule
Data Source
Figure 1A
Figure 1B
Figure 1C
AI summary
The invention provides a method for treating cancer comprising the step of administering a therapeutically effective amount of KPC1, a peptide which is at least about 70% homologous to the KPC1 or an agent which up-regulates KPC1. In some embodiments, there is also provided a method for treating cancer comprising the step of administering a therapeutically effective amount of p50, a peptide which is at least about 70% homologous to the p50 or an agent which up-regulates p50.